Serina appoints ex-Karuna CMO Brannan to board; director Gross departs

Serina Therapeutics, Inc.

Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.
Brannan led clinical strategy for KarXT, first new schizophrenia mechanism in >30 years, key to Karuna's $14B BMS acquisition.
Remy Gross departed board effective May 22, 2025; no disagreement, stays as consultant.
Filed certificate of correction to Series A Preferred Stock to add conversion price adjustment reference.

item 5.02item 5.03item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Remy Gross

Director

SER · Serina Therapeutics, Inc.

Effective: 2025-05-22
Filed: May 22, 2025 23:59 UTC

The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.

Appointed

Stephen Brannan

Director

SER · Serina Therapeutics, Inc.

Effective: 2025-05-22
Filed: May 22, 2025 23:59 UTC

On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.

Source: SEC EDGAR

accession 0001708599-25-000058

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.